PE-22-28 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
PE-22-28 is administered via subcutaneous injection (proposed) at 100-500 mcg daily once daily. Subcutaneous injections into the abdominal fat or thigh are most common. Proper reconstitution with bacteriostatic water is required first.
How Do You Inject PE-22-28?
PE-22-28 is administered via subcutaneous injection (proposed). For most researchers, subcutaneous injection is the standard approach — it's simple, relatively painless, and effective for Ion channel inhibitor peptide compounds.
This guide covers injection technique, site selection, needle choices, and common mistakes.
How Do You Prepare for a PE-22-28 Injection?
Step 1: Wash your hands thoroughly.
Step 2: Clean the top of the PE-22-28 vial and BAC water vial with alcohol swabs. If not yet reconstituted, see our PE-22-28 reconstitution guide.
Step 3: Draw your dose (100-500 mcg daily) into an insulin syringe. Use our calculator for exact units.
Step 4: Clean the injection site with an alcohol swab and let it dry.
What Is the Correct Injection Technique?
Subcutaneous (most common): Pinch a fold of skin — typically abdominal fat 2+ inches from the navel, or the thigh. Insert the needle at a 45-degree angle. Push the plunger slowly and steadily. Hold for 5 seconds, then withdraw.
Intramuscular (less common for PE-22-28): Insert the needle at 90 degrees into the muscle (deltoid or vastus lateralis). This route provides faster absorption but isn't necessary for most peptide protocols.
Rotate injection sites to prevent lipodystrophy (fat tissue changes from repeated injections in the same spot).
What Size Needle Should You Use?
For subcutaneous PE-22-28 injections, 29-31 gauge insulin needles (½ inch or 8mm) are standard. These are thin enough to be nearly painless while long enough for proper subcutaneous delivery.
Use a fresh needle for every injection. Never reuse or share needles.
Calculate Your PE-22-28 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for PE-22-28.
Open Calculator →What Are Common Injection Side Effects?
Mild redness, swelling, or itching at the injection site is normal and typically resolves within hours. Small bruises can occur, especially if you hit a capillary.
If you experience persistent pain, swelling, warmth, or redness lasting more than 24 hours, discontinue and consult a healthcare provider — these may indicate infection.
Bottom Line on PE-22-28 Injection
PE-22-28 is administered via subcutaneous injection (proposed) at 100-500 mcg daily once daily. Subcutaneous injection with a 29-31 gauge insulin needle into abdominal fat is the standard technique. Rotate sites and use a fresh needle every time.
Complete Guide
PE-22-28 : Benefits, Dosage, Side Effects & Research
Related Reading
- PE-22-28 Dosage Guide
- PE-22-28 Benefits
- PE-22-28 Side Effects
- PE-22-28 Stacking Guide
- PE-22-28 Cycle Guide
- PE-22-28 Research
Research-Grade Sourcing
If you're going to research PE-22-28, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is PE-22-28?
PE-22-28 (PE-22-28 (spadin analog, TREK-1 inhibitor)) is a Ion channel inhibitor peptide. Synthetic shortened analog of spadin with enhanced TREK-1 potassium channel specificity and brain stability. It is researched for rapid antidepressant effects (4 days vs 4-6 weeks for SSRIs), hippocampal neurogenesis, enhanced synaptogenesis.
What is the recommended PE-22-28 dosage?
Common dosages: 100-500 mcg daily administered once daily via subcutaneous injection (proposed). Cycle length: 4-8 weeks. Half-life: 14-23 hours in rodents. Use our peptide calculator for exact reconstitution math.
What are the side effects of PE-22-28?
Minimal toxicity in animal models. Potential hypertension from enhanced monoamine activity. Human safety unknown. GABAergic disruption possible.
Is PE-22-28 safe?
PE-22-28 has shown a preliminary safety profile in research. Not FDA-approved. Investigational research peptide only. All research should follow appropriate safety protocols.